BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32243242)

  • 1. Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
    Daskivich TJ; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen Z; Terris MK; Freedland SJ
    J Urol; 2020 Sep; 204(3):511-517. PubMed ID: 32243242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
    Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
    J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
    JAMA; 2005 Jul; 294(4):433-9. PubMed ID: 16046649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
    Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
    J Clin Oncol; 2007 May; 25(13):1765-71. PubMed ID: 17470867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database.
    Schiavina R; Bianchi L; Borghesi M; Briganti A; Brunocilla E; Carini M; Terrone C; Mottrie A; Dente D; Gacci M; Gontero P; Gurioli A; Imbimbo C; La Manna G; Marchioro G; Milanese G; Mirone V; Montorsi F; Morgia G; Munegato S; Novara G; Panarello D; Porreca A; Russo GI; Serni S; Simonato A; Urzì D; Verze P; Volpe A; Martorana G
    Int J Urol; 2016 Dec; 23(12):1000-1008. PubMed ID: 27620370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
    Ludwig WW; Feng Z; Trock BJ; Humphreys E; Walsh PC
    J Urol; 2018 Jan; 199(1):114-119. PubMed ID: 28818527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup.
    Moschini M; Sharma V; Zattoni F; Boorjian SA; Frank I; Gettman MT; Thompson RH; Tollefson MK; Kwon ED; Karnes RJ
    J Urol; 2016 Jun; 195(6):1773-8. PubMed ID: 26723866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
    Liesenfeld L; Kron M; Gschwend JE; Herkommer K
    J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
    Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
    Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
    J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort.
    Tilki D; Mandel P; Schlomm T; Chun FK; Tennstedt P; Pehrke D; Haese A; Huland H; Graefen M; Salomon G
    J Urol; 2015 Jun; 193(6):1970-5. PubMed ID: 25498570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy.
    Klippenstein P; Schlomm T; von Amsberg G; Beyer B; Pompe RS; Michl U; Salomon G; Thederan I; Budäus L; Heinzer H; Tilki D; Haese A; Huland H; Graefen M; Steuber T; Tennstedt P
    Urol Oncol; 2019 Sep; 37(9):575.e1-575.e7. PubMed ID: 31047783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis.
    Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
    Ann Surg Oncol; 2014 Feb; 21(2):677-83. PubMed ID: 24145996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical recurrence-free conditional probability after radical prostatectomy: A dynamic prognosis.
    García-Barreras S; Sanchez-Salas R; Mejia-Monasterio C; Muttin F; Secin F; Dell'Oglio P; Nunes-Silva I; Srougi V; Barret E; Rozet F; Prapotnich D; Cathelineau X
    Int J Urol; 2019 Jul; 26(7):725-730. PubMed ID: 31001870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.